Skip directly to local search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Volume 18, Number 8—August 2012

CME ACTIVITY

Factors Related to Increasing Prevalence of Resistance to Ciprofloxacin and Other Antimicrobial Drugs in Neisseria gonorrhoeae, United States

Edward GoldsteinComments to Author , Robert D. Kirkcaldy, David Reshef, Stuart Berman, Hillard Weinstock, Pardis Sabeti, Carlos Del Rio, Geraldine Hall, Edward W. Hook, and Marc Lipsitch
Author affiliations: Harvard School of Public Health, Boston, Massachusetts, USA (E. Goldstein, M. Lipsitch); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (R.D. Kirkcaldy, S. Berman, H. Weinstock); Oxford University, Oxford, UK (D. Reshef); Harvard University, Cambridge, Massachusetts, USA (P. Sabeti); Emory University, Atlanta (C. Del Rio); Cleveland Clinic, Cleveland, Ohio, USA (G. Hall); University of Alabama at Birmingham, Birmingham, Alabama, USA (E.W. Hook); and Jefferson County Department of Health, Birmingham (E.W. Hook)

Main Article

Figure 2

Semiannual prevalence of the ciprofloxacin (Cipro)–resistant type of Neisseria gonorrhoeae for men who have sex with men (A) and heterosexual men (B), stratified by resistance characteristics to tetracycline (tet) and penicillin (pen).

Figure 2. . . . . Semiannual prevalence of the ciprofloxacin (Cipro)–resistant type of Neisseria gonorrhoeae for men who have sex with men (A) and heterosexual men (B), stratified by resistance characteristics to tetracycline (tet) and penicillin (pen).

Main Article

Top of Page

 

Past Issues

Select a Past Issue:

Art in Science - Selections from Emerging Infectious Diseases
Now available for order



CDC 24/7 – Saving Lives, Protecting People, Saving Money. Learn More About How CDC Works For You…

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO